Future of Immuno Oncology Assays Market (2026-2033) | Cancer Immunotherapy Testing, Biomarker Discovery, Biomarker Testing & United States Growth | Top Companies 2026 - Agilent Technologies, Sysmex Corporation, Fujirebio, SRL Inc

DataM Intelligence has released a new research report titled "Immuno Oncology Assays Market Size 2025" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Immuno Oncology Assays market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/immuno-oncology-assays-market?kb

United States: Recent Industry Developments
✅ March 2026: Bristol Myers Squibb expanded its immuno-oncology diagnostics ecosystem through enhanced companion diagnostic integration supporting next-generation checkpoint inhibitor and bispecific antibody programs, strengthening precision oncology workflows.

✅ February 2026: Thermo Fisher Scientific advanced high-multiplex immuno-oncology assay panels with integrated spatial biology and flow cytometry analytics to improve tumor immune microenvironment profiling for clinical research and drug development.

✅ January 2026: Agilent Technologies upgraded multiplex immuno-oncology assay solutions with enhanced mass spectrometry compatibility, enabling deeper immune biomarker quantification and improved translational research capabilities.

✅ December 2025: QIAGEN expanded its companion diagnostic assay portfolio for immunotherapy selection, strengthening partnerships with biopharma and CRO networks to accelerate clinical trial biomarker validation.

Ready to scale in the Immuno Oncology Assays Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/immuno-oncology-assays-market?kb

List of Key Players 2026:

Merck KGaA, Thermo Fisher Scientific Inc., Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Charles River Laboratories, Bio-Techne, Creative Biolabs, Miltenyi Biotec, Adipogen Life Sciences

Growth Forecast Projected 2026:

The Global Immuno Oncology Assays Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key Developments 2025-2026:

✅ February 2026: Diagnostic companies expanded advanced immuno-oncology assay portfolios supporting tumor profiling, immune response analysis, and companion diagnostics for targeted cancer therapies.

✅ January 2026: Biotechnology firms integrated next-generation sequencing (NGS)-based assays with AI-driven analytics to improve biomarker detection accuracy and treatment response prediction.

✅ December 2025: Rising clinical adoption of multiplex immunoassays enhanced simultaneous detection of multiple immune markers, improving efficiency in cancer research and drug development workflows.

✅ November 2025: Pharmaceutical collaborations with diagnostic companies increased to co-develop companion diagnostic assays supporting immunotherapy drug approvals and precision oncology pipelines.

✅ October 2025: Expansion of automated immunoassay platforms improved laboratory throughput, reduced turnaround time, and enhanced reproducibility in oncology testing.

How Our Market Research Process Works:

The global Immuno Oncology Assays Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Immuno Oncology Assays ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:

April 2026: Gilead Sciences agreed to acquire Germany-based Tubulis for up to $5 billion, expanding its antibody-drug conjugate (ADC) and immuno-oncology pipeline.

April 2026: C4 Therapeutics expanded its strategic collaboration with Roche, a deal potentially exceeding $1 billion, focused on targeted protein degradation for oncology applications.

April 2026: Boston Oncology CGT entered a licensing agreement with Xuanzhu Biopharmaceutical for oncology assets across multiple regions, with a deal value potentially exceeding $100 million plus milestones.

March 2026: Gilead Sciences completed acquisition of Ouro Medicines (T-cell engager platform), strengthening immuno-oncology and immune-modulation pipeline (deal value up to $2.2 billion) (reported via biotech deal disclosures)

Request Strategic Market Customization: https://datamintelligence.com/customize/immuno-oncology-assays-market?kb

Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical expanded immuno-oncology biomarker research collaborations focused on next-generation immune profiling to support personalized cancer immunotherapy development.

✅ February 2026: Sysmex Corporation advanced automated immuno-oncology assay platforms integrating digital pathology and AI-based cell analysis for improved cancer immune response evaluation.

✅ January 2026: Fujirebio strengthened its immuno-oncology diagnostic pipeline with enhanced immunoassay kits targeting immune checkpoint biomarkers for precision oncology applications.

✅ December 2025: SRL Inc. expanded clinical laboratory testing services for immuno-oncology biomarkers, supporting increased demand for companion diagnostics in oncology trials.

Major Focused Key Segmentations 2026:

Product Type Outlook: Instruments, Consumables, Software and Services

By Assay Type: Cell Proliferation Assays, Cell Migration and Invasion Assays, Phagocytosis Assays, Immune Cell Killing Assays, Others

By Technology Outlook: PCR, NGS, Immunoassay, Flow Cytometry, Others

By Indication Outlook: Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, Others

By End User Outlook: Academic Institutes, Research Organizations, Diagnostics Centers, Others,

Regional Growth Analysis for Market:

⇥ North America - Dominates the immuno-oncology assays market due to strong clinical research infrastructure, high cancer prevalence, and rapid adoption of advanced biomarker-based testing.

⇥ Asia-Pacific (including Japan) - Shows strong expansion driven by increasing cancer research investments, growing biotech manufacturing, and rising adoption of precision oncology diagnostics in countries like China, India, and Japan.

⇥ Europe - Witnesses steady growth supported by government-funded oncology research programs, expanding clinical trials, and increasing focus on personalized cancer treatment approaches.

⇥ Middle East & Africa - Emerging market with gradual adoption of immuno-oncology testing, supported by improving healthcare infrastructure and growing awareness of early cancer diagnostics.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=immuno-oncology-assays-market?kb

FAQ

Q1: What is the current size of the Immuno Oncology Assays Market?

A: The Immuno Oncology Assays Market was valued at US$ 6.11 Billion in 2024 and is forecasted to hit US$ 17.96 Billion by 2033

Q2: How rapidly will the Market expanding?

A: The Immuno Oncology Assays market is projected to grow at a CAGR of 12.8% between 2025 and 2033.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.